Gad Berdugo, MBA, MSc

Based in New York City, Mr. Berdugo brings over 25 years of biotech corporate & business development, strategy, operational, financial, investment and venture general management experience. He is currently an Executive in Residence at Columbia Technology Ventures and the Vice-Chairman of the Board of clinical stage, precision oncology company, Diaccurate. He served as CBO at CRISPR gene editing pioneer Editas (Nasdaq: EDIT); Co-Founder and CEO of personalized neoantigen cancer vaccine venture, EpiVax Oncology Inc.; CFO at Immune Pharmaceuticals Inc. (Nasdaq: IMDP); Managing Director and Head of Life Sciences at Tegris Advisors; Director, Senior Equity Research Analyst and Life Sciences Sector Leader at Lazard, Asset Management Group. Prior to that, he served as a Director of Global Business Development at Baxter’s Biopharmaceuticals Group and started his career at Abbott Labs. Mr. Berdugo received his BSc with Honors from Imperial College London, his MSc in Biochemical Engineering from University College London and his MBA from HEC Paris.